Cover Image

Nanotechnology tools for infection control : scanning new horizons on next-generation therapies to eradicate pathogens and fight drug resistance /

This book explores new technologies and strategies in the fight against pathogens and drug resistance, focusing on the role of biomaterials, tissue engineering, and nanotechnology. Edited by Alessandro Poma and Loris Rizzello, it delves into the challenges faced by pharmaceutical companies in antimi...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Format: eBook
Language:English
Published: Amsterdam : Elsevier, [2025].
Series:Micro and nano technologies series
Subjects:
Communicable diseases.
Nanomedicine.
Communicable Diseases
Nanomedicine
Maladies infectieuses.
Nanomédecine.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • Nanotechnology Tools for Infection Control
  • Nanotechnology Tools for Infection Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance
  • Copyright
  • Contents
  • Contributors
  • 1
  • Introduction
  • 2
  • The significant drain in antimicrobial discovery by pharma companies
  • 1. Introduction and historical background
  • 2. Challenges and role of drugmakers
  • 3. Quest for antimicrobial drug design
  • 3.1 Few weapons against a bigger challenge: AMR
  • 4. Pharmaceutical development in a 'green way'
  • 5. New technologies, devices for diagnostics and toxicology
  • 5.1 Start-ups in the field of antimicrobial synthesis
  • 5.2 Start ups active in the field of microfluidics/organ on a chip for diagnostics in antimicrobial and AMR
  • 6. Active public and private initiatives against AMR
  • 7. Final remarks and perspectives
  • References
  • 3
  • Design and production of nanoparticles
  • 1. Choice of material
  • 1.1 Inorganic materials
  • 1.2 Lipids
  • 1.3 Polypeptides
  • 1.4 Block-copolymers
  • 2. Nanoparticles
  • 2.1 Lipid nanoparticles
  • 2.2 Peptide-based nanoparticles
  • 2.3 Polymeric nanoparticles
  • 2.3.1 Micelles and multi-compartment-micelles
  • 2.3.2 Polymeric nanospheres
  • 2.3.3 Polymeric vesicles
  • 3. Production of nanoparticles
  • 3.1 Bottom-up production
  • 3.2 Top-down production
  • 3.3 Microfluidics
  • 4. Examples of commercialised applications
  • References
  • 4
  • Nanoparticle characterisation and standardisation
  • 1. Introduction
  • 2. Sample preparation
  • 2.1 Sampling
  • 2.2 Powder samples
  • 2.3 Colloidal samples
  • 3. Measurements of nanoparticle properties
  • 3.1 Size
  • 3.1.1 AFM
  • 3.1.2 Electron microscopies
  • 3.1.3 TRPS
  • 3.1.4 Scattering-based methods
  • 3.1.5 CLS
  • 3.1.6 spICP-MS
  • 3.1.7 General considerations
  • 3.1.8 Examples
  • 3.2 Morphology.
  • 3.3 Surface composition characteristics
  • 3.3.1 Zeta-potential
  • 3.3.2 Surface chemistry
  • 3.4 Other properties
  • 3.5 Measuring nanoparticles in biological environments
  • 4. Considerations when selecting a technique
  • 4.1 Sample type
  • 4.2 Sample state
  • 4.3 Sample quantity
  • 4.4 Accuracy and precision
  • 5. Standardisation
  • 5.1 What, why and how
  • 5.2 International standardisation in nanotechnologies
  • 5.3 International standardisation in antimicrobial properties
  • 6. Conclusion and perspectives
  • References
  • 5
  • Navigating the nanoscale: Principles of body navigation
  • 1. Introduction
  • 2. Modulating nanoparticle pharmacodynamics: Avoiding liver and RES clearance
  • 2.1 The liver architecture and location of scavenger RE cells within the liver affect their interaction with nanomedicines
  • 2.2 Preconditioning adjuvant strategies of the liver microenvironment to reduce nanomedicines clearance mechanisms
  • 2.2.1 Depletion of opsonic proteins
  • 2.2.2 Dysopsonin corona formation
  • 2.2.3 Transient depletion of RE cells
  • 2.2.4 Pharmacological inhibition of endocytosis
  • 2.2.5 Preinduced physical saturation of phagocytic cell activity
  • 2.2.5.1 Scavenger receptor (SR) ligands
  • 2.2.5.2 RES blockade
  • 2.2.5.3 RES cytoblockade
  • 2.2.6 Transient and selective stealth coating of the scavenger sinusoidal wall
  • 3. Brain targeting: Crossing the blood-brain barrier
  • 3.1 The blood-brain barrier
  • 3.2 Current strategies to achieve nanoparticle brain targeting
  • 3.2.1 Nanoparticle functionalisation targeting channel-transporter proteins
  • 3.2.2 Nanoparticle functionalisation targeting endocytic receptors
  • 3.3 Nanoparticle avidity as a modulator of transcytosis
  • 3.4 Generating brain-specific targets
  • 3.5 Delivering NPs to treat brain infections
  • 4. Brain targeting: Delivery, targeting and efflux within the brain parenchyma.
  • 4.1 Components of the brain parenchyma
  • 4.2 Movement of fluids in the brain
  • 4.3 Movement of NPs within the brain fluids
  • 5. Tumour targeting: Peripheral cancers
  • 5.1 EPR effect
  • 5.2 Smart nanotherapeutics
  • 5.2.1 Microenvironment-responsive nanotherapeutics
  • 5.2.2 Externally triggerable nanotherapeutics
  • 5.2.3 Actively targeted nanotherapeutics
  • 5.3 Microenvironment heterogeneity
  • 5.4 Microenvironment-reprogramming strategies for rejuvenating nanotherapeutics
  • 5.4.1 Amplification of tissue accumulation
  • 5.4.2 Amplification of the responsiveness of nanotherapeutics
  • 6. Immune system targeting
  • 6.1 Targeting immune system organs and their associated immune cells using NPs
  • 6.2 Targeting immune cells for vaccination
  • References
  • Further reading
  • 6
  • Intracellular fate of nanosystems, their degradation and body accumulation
  • 1. Introduction
  • 2. The fate of nanoparticles
  • 2.1 Preliminary considerations on NPs toxicity
  • 2.2 NPs interfacing with biological barriers: An overview on the intra-body itineraries
  • 2.3 Targeting the cellular barriers
  • 2.4 Cellular uptake of NPs
  • 2.5 Intracellular fate and sorting of NPs
  • 2.6 The tissue barriers
  • 2.7 The body clearance of NPs
  • 3. Concluding remarks
  • References
  • 7
  • Molecular targets and pharmacodynamics for bactericidal and bacteriostatic activity
  • 1. Antimicrobial agents, mechanisms and modes of delivery
  • 1.1 Clinical need for antimicrobial agents
  • 1.2 Modes of action of antimicrobial agents
  • 1.3 Antimicrobial resistance mechanisms
  • 1.3.1 Changes in permeability
  • 1.3.2 Efflux pumps
  • 1.3.3 Modification and protection of the target site
  • 1.3.4 Inactivation or degradation of antibiotics
  • 1.4 Novel modes of delivery of antimicrobial agents
  • 2. Applications of antimicrobial nanoparticles, pharmacodynamics and safety
  • 2.1 Nanoparticles.
  • 9
  • Pre-clinical characterisation: Which animal model is best for infection?
  • 1. Zebrafish, a tiny vertebrate star
  • 2. Why studying NPs in the zebrafish
  • 3. Zebrafish, nanoparticles and intracellular infections
  • 4. Conventional models
  • References
  • 10
  • Clinical translation and envisioned impact of nanotech for infection control: Economy, government policy and public aw ...
  • 1. Introduction: Why nanotechnology against infections?
  • 2. The background of the resistance problem and perception of nanotech
  • 2.1 Resistance problem and antibiotic abuse
  • 2.2 Nanomedicine, promising or not?
  • 3. Nanotoxicology, environmental risks and regulatory policy
  • 4. Economical perspective towards clinical translation
  • 4.1 Antimicrobial nanoparticles translational scenario
  • 4.1.1 Liposomal NPs
  • 4.1.2 Inorganic NPs
  • 4.2 Issues to focus on in clinical translation
  • 5. Conclusions
  • References
  • Index
  • Back Cover.